Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 1/20 | 0.44 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.44 |
| ▸ | AAK1 | Q2M2I8 | 5/20 | 0.42 |
| ▸ | BACE1 | P56817 | 1/20 | 0.35 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.35 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.34 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.33 |
| ▸ | BCHE | P06276 | 1/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.32 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16532832 | 0.92 | AAK1 (0.44) | PRMT5WDR77AAK1BACE1BACE2 | |
| SCHEMBL15116827 | 0.87 | AAK1 (0.52) | PRMT5WDR77AAK1 | |
| SCHEMBL20054464 | 0.87 | AAK1 (0.52) | PRMT5WDR77AAK1 | |
| SCHEMBL19184968 | 0.82 | AAK1 (0.46) | PRMT5WDR77AAK1BACE1BACE2 | |
| SCHEMBL16515607 | 0.80 | SCN10A (0.36) | PRMT5WDR77AAK1DGAT1KMT2A | |
| SCHEMBL15116600 | 0.79 | AAK1 (0.42) | PRMT5WDR77AAK1BACE1BACE2 | |
| SCHEMBL20054411 | 0.79 | AAK1 (0.42) | PRMT5WDR77AAK1BACE1BACE2 | |
| SCHEMBL18440464 | 0.79 | PRMT5 (0.36) | PRMT5WDR77AAK1BACE1BACE2 | |
| SCHEMBL20468222 | 0.79 | AAK1 (0.43) | PRMT5WDR77AAK1BACE1BACE2 | |
| SCHEMBL23705464 | 0.78 | PRMT5 (0.57) | PRMT5WDR77AAK1BACE1BACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10617675-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-04-14 | — | — | US | disclosed |
| US-20180221342-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10617675-B2 | Hepatitis C virus inhibitors | HAVCR2, MAVS, EIF2AK2 | PRMT5 2123/4885WDR77 3323/4885AAK1 2213/4885 |
| US-20180221342-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, MAVS, EIF2AK2 | PRMT5 2123/4885WDR77 3323/4885AAK1 2213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.